The University of Southampton
University of Southampton Institutional Repository

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.
A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue.
Background: cancer-related fatigue is an important clinical problem. It is common, distressing, and often difficult to treat. There is a role for drug treatment of cancer-related fatigue, but no consensus has been reached on which drugs are useful. This systematic review and meta-analysis aims to review the available evidence and make recommendations for practice and research.
Methods: we searched the Cochrane register of controlled trials (through the second quarter 2007), Medline (January 1, 1966, through August 1, 2007), and EMBASE (January 1, 1980, through August 1, 2007) by use of a predetermined list of search terms. Cochrane Collaboration meta-analysis review methodology was used for this study. The change in fatigue score on the instrument used in each study and other outcomes of interest (adverse events and withdrawal rates) were compared between treatment and control arms by use of the standardized mean difference (SMD) with 95% confidence intervals (CIs). All statistical tests were two-sided.
Results: we identified 27 eligible trials of drug treatments for cancer-related fatigue (with a total of 6746 participants). The overall effect size for all drug classes was small. A meta-analysis of two studies (n = 264 patients) indicated that methylphenidate (a psychostimulant) was superior to placebo (standardized mean difference [SMD] in change in fatigue score = –0.30, 95% confidence interval [CI] = –0.54 to –0.05; P = .02) for treating cancer-related fatigue. A meta-analysis of 10 studies (n = 2226 patients) evaluating erythropoietin in anemic cancer patients who were undergoing chemotherapy indicated that erythropoietin was superior to placebo (SMD = –0.30, 95% CI = –0.46 to –0.29; P = .008). Among anemic patients (four studies with n = 964 patients), improvement in fatigue was associated with darbepoetin treatment compared with placebo treatment (SMD = –0.13, 95% CI = –0.27 to 0.00; P = .05). Progestational steroids and paroxetine were no better than placebo in the treatment of cancer-related fatigue.
Conclusions: there is some evidence that treatment of cancer-related fatigue with methylphenidate appears to be effective. More robust evidence indicates that treatment with hematopoietic agents appears to relieve cancer-related fatigue caused by chemotherapy-induced anemia. Further confirmatory trials are required for both observations
0027-8874
1155-1166
Minton, Ollie
67220849-ee0e-4b3d-89f6-9ad96a168d84
Richardson, Alison
3db30680-aa47-43a5-b54d-62d10ece17b7
Sharpe, Michael
7c77f2a0-2b8a-42b2-beda-afa88edf4ab3
Hotopf, Matthew
5a23f5d8-579f-4386-ae4b-07bfebe1b5fa
Stone, Patrick
11102a4e-73f3-408a-b94a-5aece312508f
Minton, Ollie
67220849-ee0e-4b3d-89f6-9ad96a168d84
Richardson, Alison
3db30680-aa47-43a5-b54d-62d10ece17b7
Sharpe, Michael
7c77f2a0-2b8a-42b2-beda-afa88edf4ab3
Hotopf, Matthew
5a23f5d8-579f-4386-ae4b-07bfebe1b5fa
Stone, Patrick
11102a4e-73f3-408a-b94a-5aece312508f

Minton, Ollie, Richardson, Alison, Sharpe, Michael, Hotopf, Matthew and Stone, Patrick (2008) A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue. JNCI Journal of the National Cancer Institute, 100 (16), 1155-1166. (doi:10.1093/jnci/djn250).

Record type: Article

Abstract

Background: cancer-related fatigue is an important clinical problem. It is common, distressing, and often difficult to treat. There is a role for drug treatment of cancer-related fatigue, but no consensus has been reached on which drugs are useful. This systematic review and meta-analysis aims to review the available evidence and make recommendations for practice and research.
Methods: we searched the Cochrane register of controlled trials (through the second quarter 2007), Medline (January 1, 1966, through August 1, 2007), and EMBASE (January 1, 1980, through August 1, 2007) by use of a predetermined list of search terms. Cochrane Collaboration meta-analysis review methodology was used for this study. The change in fatigue score on the instrument used in each study and other outcomes of interest (adverse events and withdrawal rates) were compared between treatment and control arms by use of the standardized mean difference (SMD) with 95% confidence intervals (CIs). All statistical tests were two-sided.
Results: we identified 27 eligible trials of drug treatments for cancer-related fatigue (with a total of 6746 participants). The overall effect size for all drug classes was small. A meta-analysis of two studies (n = 264 patients) indicated that methylphenidate (a psychostimulant) was superior to placebo (standardized mean difference [SMD] in change in fatigue score = –0.30, 95% confidence interval [CI] = –0.54 to –0.05; P = .02) for treating cancer-related fatigue. A meta-analysis of 10 studies (n = 2226 patients) evaluating erythropoietin in anemic cancer patients who were undergoing chemotherapy indicated that erythropoietin was superior to placebo (SMD = –0.30, 95% CI = –0.46 to –0.29; P = .008). Among anemic patients (four studies with n = 964 patients), improvement in fatigue was associated with darbepoetin treatment compared with placebo treatment (SMD = –0.13, 95% CI = –0.27 to 0.00; P = .05). Progestational steroids and paroxetine were no better than placebo in the treatment of cancer-related fatigue.
Conclusions: there is some evidence that treatment of cancer-related fatigue with methylphenidate appears to be effective. More robust evidence indicates that treatment with hematopoietic agents appears to relieve cancer-related fatigue caused by chemotherapy-induced anemia. Further confirmatory trials are required for both observations

Full text not available from this repository.

More information

Published date: August 2008

Identifiers

Local EPrints ID: 69132
URI: https://eprints.soton.ac.uk/id/eprint/69132
ISSN: 0027-8874
PURE UUID: ca46c982-a64b-4383-9479-a705760e3955
ORCID for Alison Richardson: ORCID iD orcid.org/0000-0003-3127-5755

Catalogue record

Date deposited: 11 Nov 2009
Last modified: 10 Dec 2019 01:40

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of https://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×